Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke - Way to endeavor

被引:33
|
作者
Huang, Poyin [1 ]
Chen, Chun-Hung [1 ]
Yang, Yuan-Han [1 ]
Lin, Ruey-Tay [1 ]
Lin, Feng-Cheng [1 ]
Liu, Ching-Kuan [1 ]
机构
[1] Kaohsiung Med Univ, Chung Ho Mem Hosp 100, Dept Neurol, Kaohsiung 807, Taiwan
关键词
eligibility; stroke; tissue plasminogen activator; stroke code;
D O I
10.1159/000094994
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The eligibility for recombinant tissue plasminogen activator (rtPA) is rare. We analyze the reasons for exclusion from rtPA among patients who were admitted to our hospital within 3 h. Methods: A strict protocol for hyper-acute stroke was set in a university teaching hospital. Consecutive patients activating the protocol from June 2004 to October 2005 were prospectively registered and entered into a computerized database. The patients were excluded from rtPA according to the modified exclusion criteria from the National Institute of Neurological Disorders and Stroke rtPA trial. Results: Of the 182 patients activating the protocol, only 11 (6.04%) received intravenous rtPA and 4 (2.2%) IA thrombolysis. Patients were excluded for multiple reasons, and the main reasons for exclusion were minor or improving stroke (46.15%), hypertension (35.16%), insufficient time to complete studies or onset beyond 3 h after reconfirmation (24.17%) and intracranial hemorrhage (15.93%). Of 167 excluded patients, 72 (43.11%) were excluded by a single criterion, 53 (31.73%) by 2 criteria and 29 (17.36%) by 3 criteria. The mean time from hospital arrival to presentation to a neurologist was 9.24 +/- 15.11 min (n = 164, median = 8.00, mode = 10, range = 0-65). The mean time from hospital arrival to computed tomography (CT) was 21.67 +/- 23.95 min (n = 167, median = 20.00, mode = 10, range = 4-68). Conclusion: An intrahospital stroke code was implemented to minimize intrahospital delay. However, only 11 patients received intravenous rtPA and 4 IA thrombolysis at our hospital from June 2004 to October 2005. The result brings into question the neurologist's conservative interpretation of the criteria and the necessity to clearly define some criteria. Furthermore an intrahospital stroke code should also be implemented for inpatients to maximize the eligibility for rtPA. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:423 / 428
页数:6
相关论文
共 50 条
  • [22] The Emerging Role of Recombinant Tissue Plasminogen Activator in Improving Neuroplasticity in Patients With Acute Ischemic Stroke
    Soliman, Rasha
    Mamdoh, Hend
    Hussein, Mona
    Rashed, Laila
    NEUROLOGY, 2019, 92 (15)
  • [23] Systemic thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: first Croatian experiences
    Vesna Matijević
    Domagoj Alvir
    Branko Malojčić
    Lea Unušić
    Svjetlana Šupe
    Marina Boban
    Andrea Bujan-Kovač
    Mario Habek
    Zdravka Poljaković
    Neurological Sciences, 2010, 31 : 693 - 697
  • [24] Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke
    Ernst, R
    Pancioli, A
    Tomsick, T
    Kissela, B
    Woo, D
    Kanter, D
    Jauch, E
    Carrozzella, J
    Spilker, J
    Broderick, J
    STROKE, 2000, 31 (11) : 2552 - 2557
  • [25] From clinical trial to clinical practice:: Recombinant tissue plasminogen activator in acute ischemic stroke
    Heiss, WD
    Grond, M
    Schmülling, S
    Rudolf, J
    Stenzel, C
    Neveling, M
    ANNALS OF NEUROLOGY, 1998, 44 (03) : 520 - 520
  • [26] Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke
    Tanne, David
    Macko, Richard F.
    Lin, Yan
    Tilley, Barbara C.
    Levine, Steven R.
    STROKE, 2006, 37 (07) : 1798 - 1804
  • [27] Intravenous Thrombolysis With Low-Dose Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke
    Loh, Pei Kee
    Sharma, Vijay K.
    STROKE, 2010, 41 (03) : E164 - E164
  • [28] The use of recombinant tissue plasminogen activator in in acute ischemic stroke is associated with increased level of BDNF
    Rasha Soliman
    Hend Mamdouh
    Laila Rashed
    Mona Hussein
    Journal of Thrombosis and Thrombolysis, 2021, 52 : 1165 - 1172
  • [29] Simultaneous Administration of Recombinant Tissue Plasminogen Activator and Edaravone in Acute Cerebral Ischemic Stroke Patients
    Takenaka, Katsunobu
    Kato, Masayasu
    Yamauti, Keita
    Hayashi, Katsuhiko
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2014, 23 (10): : 2748 - 2752
  • [30] Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator
    Fassbender, K
    Dempfle, CE
    Mielke, O
    Schwartz, A
    Daffertshofer, M
    Eschenfelder, C
    Dollman, M
    Hennerici, M
    STROKE, 1999, 30 (10) : 2101 - 2104